Johnson & Johnson's Form 4/A amendment
AmendedCVRx, Inc. (CVRX) · filed Jan 8, 2026
- Accession no.
- 0001193125-26-007679
- Filed
- Jan 8, 2026, 4:05 PM ET
- Trade date
- Nov 25-26, 2025
- Filing delay
- 44 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Dec 1, 2025
This filing lists 2 non-derivative transactions. Open-market sales total $224.0K. It was filed 44 days after the trade.
This amendment replaces 0001193125-25-303876 (filed Dec 1, 2025).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Johnson & JohnsonCIK 0000200406 | 10% Owner |
| Johnson & Johnson Innovation - JJDC, Inc.CIK 0000924020 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.22. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.23. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
This Amendment to the Form 4 filed on 12/01/2025 is being filed to include the sale of shares on 11/25/2025, which was inadvertently omitted from the original filing due to an administrative oversight.